Symbols / LBRX Stock $30.73 -0.15% LB Pharmaceuticals Inc

Healthcare • Biotechnology • United States • NGM
LBRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Heather D. Turner Esq., J.D.
Exch · Country NGM · United States
Market Cap 881.18M
Enterprise Value 590.82M
Income -25.20M
Sales —
FCF (ttm) -27.23M
Book/sh 11.91
Cash/sh 10.29
Employees 27
Insider 10d —
IPO Sep 11, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.20
PEG —
P/S —
P/B 2.58
P/C —
EV/EBITDA -20.25
EV/Sales —
Quick Ratio 39.67
Current Ratio 41.45
Debt/Eq 1.18
LT Debt/Eq —
EPS (ttm) -3.13
EPS next Y -4.27
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-03-26
ROA -10.65%
ROE -15.70%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 28.67M
Shs Float 19.71M
Insider Own 0.27%
Instit Own 96.53%
Short Float 9.63%
Short Ratio 10.43
Short Interest 2.62M
52W High 32.91
vs 52W High -6.61%
52W Low 13.36
vs 52W Low 130.01%
Beta —
Impl. Vol. —
Rel Volume 0.75
Avg Volume 256.59K
Volume 191.35K
Target (mean) $43.80
Tgt Median $36.00
Tgt Low $31.00
Tgt High $78.00
# Analysts 5
Recom Strong_buy
Prev Close $30.77
Price $30.73
Change -0.15%
About

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$43.80
Mean price target
2. Current target
$30.73
Latest analyst target
3. DCF / Fair value
$-17.09
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.73
Low
$31.00
High
$78.00
Mean
$43.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 init Craig-Hallum — → Buy $36
2026-03-27 main Stifel Buy → Buy $40
2025-12-11 main Stifel Buy → Buy $35
2025-10-06 init Stifel — → Buy $27
2025-10-06 init Piper Sandler — → Overweight $78
2025-10-06 init Leerink Partners — → Outperform $34
News
RSS: Latest LBRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-09-12 NUSSBAUM RAN Director — 1,000,000 $15.00 $15,000,000
2025-09-12 NUSSBAUM RAN Director — 411,681 — —
2025-09-12 PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. Beneficial Owner of more than 10% of a Class of Security — 1,000,000 $15.00 $15,000,000
2025-09-12 PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. Beneficial Owner of more than 10% of a Class of Security — 411,681 — —
2025-09-12 VIDA VENTURES GP III, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 333,333 $15.00 $4,999,995
2025-09-12 VIDA VENTURES GP III, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 548,910 — —
2025-09-12 DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD Beneficial Owner of more than 10% of a Class of Security — 2,666,666 $15.00 $39,999,990
2025-09-12 DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD Beneficial Owner of more than 10% of a Class of Security — 686,138 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
30.40
-53.10%
64.83
+469.88%
11.38
+304.98%
2.81
Research And Development
16.74
-67.28%
51.17
+552.28%
7.84
+482.84%
1.35
Selling General And Administration
13.66
+0.01%
13.66
+286.83%
3.53
+141.35%
1.46
General And Administrative Expense
13.66
+0.01%
13.66
+286.83%
3.53
+141.35%
1.46
Other Gand A
13.66
+0.01%
13.66
+286.83%
3.53
+141.35%
1.46
Total Expenses
30.40
-53.10%
64.83
+469.88%
11.38
+304.98%
2.81
Operating Income
-30.40
+53.10%
-64.83
-469.88%
-11.38
-304.98%
-2.81
Total Operating Income As Reported
-30.40
+53.10%
-64.83
-469.88%
-11.38
-304.98%
-2.81
EBITDA
-30.08
+53.53%
-64.74
-4380.21%
-1.45
+88.15%
-12.19
Normalized EBITDA
-31.36
+51.56%
-64.75
-511.11%
-10.60
-286.82%
-2.74
Reconciled Depreciation
0.32
+252.75%
0.09
+2175.00%
0.00
+100.00%
0.00
EBIT
-30.40
+53.10%
-64.83
-4374.12%
-1.45
+88.12%
-12.20
Total Unusual Items
1.28
+15900.00%
0.01
-99.91%
9.15
+196.77%
-9.46
Total Unusual Items Excluding Goodwill
1.28
+15900.00%
0.01
-99.91%
9.15
+196.77%
-9.46
Special Income Charges
—
0.00
+100.00%
-7.43
0.00
Other Special Charges
—
—
7.43
—
Net Income
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Pretax Income
-25.20
+60.06%
-63.10
-905.75%
-6.27
+56.27%
-14.35
Net Non Operating Interest Income Expense
3.92
+127.77%
1.72
+142.87%
-4.01
-93.17%
-2.08
Interest Expense Non Operating
—
0.00
-100.00%
4.83
+124.31%
2.15
Net Interest Income
3.92
+127.77%
1.72
+142.87%
-4.01
-93.17%
-2.08
Interest Expense
—
0.00
-100.00%
4.83
+124.31%
2.15
Interest Income Non Operating
3.92
+127.77%
1.72
+112.21%
0.81
+1010.96%
0.07
Interest Income
3.92
+127.77%
1.72
+112.21%
0.81
+1010.96%
0.07
Other Income Expense
1.28
+15900.00%
0.01
-99.91%
9.12
+196.36%
-9.46
Other Non Operating Income Expenses
—
—
-0.03
-580.00%
-0.01
Gain On Sale Of Security
1.28
+15900.00%
0.01
-99.95%
16.59
+275.41%
-9.46
Tax Provision
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-1.99
Net Income Including Noncontrolling Interests
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Net Income From Continuing Operation Net Minority Interest
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Net Income From Continuing And Discontinued Operation
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Net Income Continuous Operations
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Normalized Income
-26.48
+58.03%
-63.11
-309.14%
-15.43
-124.25%
-6.88
Net Income Common Stockholders
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Diluted EPS
—
-17.82
-905.61%
-1.77
+56.27%
-4.05
Basic EPS
—
-17.82
-905.61%
-1.77
+56.27%
-4.05
Basic Average Shares
—
3.54
+0.00%
3.54
+0.00%
3.54
Diluted Average Shares
—
22.44
+0.00%
22.44
+0.00%
22.44
Diluted NI Availto Com Stockholders
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
312.93
+833.18%
33.53
-26.55%
45.66
+112.44%
21.49
Current Assets
308.43
+968.01%
28.88
-36.72%
45.63
+112.36%
21.49
Cash Cash Equivalents And Short Term Investments
295.21
+954.37%
28.00
-35.32%
43.29
+102.26%
21.40
Cash And Cash Equivalents
250.17
+988.75%
22.98
+53.40%
14.98
-30.02%
21.40
Other Short Term Investments
45.04
+797.03%
5.02
-82.27%
28.31
0.00
Prepaid Assets
12.74
+1603.34%
0.75
-67.72%
2.32
+2948.68%
0.08
Current Deferred Assets
—
0.00
-100.00%
0.01
—
Other Current Assets
0.48
+262.12%
0.13
+528.57%
0.02
+133.33%
0.01
Total Non Current Assets
4.50
-3.29%
4.66
+20139.13%
0.02
+666.67%
0.00
Net PPE
3.73
-10.22%
4.16
+17973.91%
0.02
+666.67%
0.00
Gross PPE
4.15
-2.49%
4.26
+12423.53%
0.03
+240.00%
0.01
Accumulated Depreciation
-0.42
-315.84%
-0.10
-818.18%
-0.01
-57.14%
-0.01
Properties
0.00
0.00
0.00
—
Machinery Furniture Equipment
0.51
+8.74%
0.47
+1279.41%
0.03
+240.00%
0.01
Other Properties
2.15
-6.40%
2.30
—
—
Leases
1.49
+0.00%
1.49
0.00
—
Other Non Current Assets
0.77
+54.62%
0.50
—
—
Total Liabilities Net Minority Interest
11.62
-90.92%
128.09
+59.85%
80.13
+59.29%
50.30
Current Liabilities
7.44
-8.23%
8.11
+211.17%
2.61
+455.65%
0.47
Payables And Accrued Expenses
4.52
-16.06%
5.38
+197.62%
1.81
+629.03%
0.25
Payables
2.13
-8.32%
2.32
+67.03%
1.39
+790.38%
0.16
Accounts Payable
2.13
-8.32%
2.32
+67.03%
1.39
+790.38%
0.16
Current Accrued Expenses
2.39
-21.92%
3.06
+630.55%
0.42
+355.43%
0.09
Pensionand Other Post Retirement Benefit Plans Current
2.19
-2.05%
2.24
+180.83%
0.80
+261.09%
0.22
Current Debt And Capital Lease Obligation
0.73
+49.90%
0.49
—
—
Current Capital Lease Obligation
0.73
+49.90%
0.49
0.00
—
Total Non Current Liabilities Net Minority Interest
4.18
-96.51%
119.98
+54.76%
77.52
+55.56%
49.84
Long Term Debt And Capital Lease Obligation
2.84
-11.72%
3.22
0.00
-100.00%
24.15
Long Term Debt
—
—
—
24.15
Long Term Capital Lease Obligation
2.84
-11.72%
3.22
0.00
—
Preferred Securities Outside Stock Equity
0.00
-100.00%
114.26
+50.41%
75.97
+955.98%
7.19
Stockholders Equity
301.31
+418.66%
-94.55
-174.28%
-34.47
-19.65%
-28.81
Common Stock Equity
301.31
+418.66%
-94.55
-174.28%
-34.47
-19.65%
-28.81
Capital Stock
0.00
+200.00%
0.00
+0.00%
0.00
+0.00%
0.00
Common Stock
0.00
+200.00%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
25.30
+12.73%
22.44
+0.00%
22.44
+0.00%
22.44
Ordinary Shares Number
25.30
+12.73%
22.44
+0.00%
22.44
+0.00%
22.44
Additional Paid In Capital
430.67
+4359.64%
9.66
+49.19%
6.47
+5.54%
6.13
Retained Earnings
-129.53
-24.16%
-104.32
-153.08%
-41.22
-17.96%
-34.95
Gains Losses Not Affecting Retained Earnings
0.17
+51.35%
0.11
-59.49%
0.27
0.00
Other Equity Adjustments
0.17
+51.35%
0.11
-59.49%
0.27
—
Total Equity Gross Minority Interest
301.31
+418.66%
-94.55
-174.28%
-34.47
-19.65%
-28.81
Total Capitalization
301.31
+418.66%
-94.55
-174.28%
-34.47
-639.13%
-4.66
Working Capital
300.99
+1349.16%
20.77
-51.73%
43.03
+104.70%
21.02
Invested Capital
301.31
+418.66%
-94.55
-174.28%
-34.47
-639.13%
-4.66
Total Debt
3.57
-3.62%
3.70
0.00
-100.00%
24.15
Net Debt
—
—
—
2.74
Capital Lease Obligations
3.57
-3.62%
3.70
0.00
—
Net Tangible Assets
301.31
+418.66%
-94.55
-174.28%
-34.47
-19.65%
-28.81
Tangible Book Value
301.31
+418.66%
-94.55
-174.28%
-34.47
-19.65%
-28.81
Derivative Product Liabilities
1.34
-46.37%
2.50
+60.82%
1.56
-91.08%
17.45
Non Current Accrued Expenses
—
—
0.00
-100.00%
1.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-35.21
+33.63%
-53.05
-338.66%
-12.09
-343.33%
-2.73
Cash Flow From Continuing Operating Activities
-35.21
+33.63%
-53.05
-338.66%
-12.09
-343.33%
-2.73
Net Income From Continuing Operations
-25.20
+60.06%
-63.10
-905.61%
-6.28
+56.27%
-14.35
Depreciation Amortization Depletion
0.32
+252.75%
0.09
+2175.00%
0.00
+100.00%
0.00
Depreciation
0.32
+252.75%
0.09
+2175.00%
0.00
+100.00%
0.00
Depreciation And Amortization
0.32
+252.75%
0.09
+2175.00%
0.00
+100.00%
0.00
Other Non Cash Items
0.15
-52.27%
0.31
-92.14%
3.92
+137.97%
1.65
Stock Based Compensation
4.19
+32.58%
3.16
+971.53%
0.29
-31.55%
0.43
Asset Impairment Charge
0.00
-100.00%
3.22
0.00
—
Operating Gains Losses
-1.27
-15800.00%
-0.01
+99.91%
-9.15
-196.77%
9.46
Gain Loss On Investment Securities
-1.28
-15900.00%
-0.01
+99.95%
-16.59
-275.41%
9.46
Gain Loss On Sale Of PPE
0.01
0.00
—
—
Change In Working Capital
-13.65
-512.04%
3.31
+352.32%
-1.31
-1626.74%
0.09
Change In Receivables
-0.27
-335.09%
0.11
+174.03%
-0.15
—
Change In Prepaid Assets
-12.34
-602.28%
-1.76
+22.15%
-2.26
-4915.56%
-0.04
Change In Payables And Accrued Expense
-0.91
-118.14%
5.02
+356.83%
1.10
+738.17%
0.13
Change In Other Current Liabilities
-0.13
-123.33%
-0.06
0.00
—
Investing Cash Flow
-39.89
-271.68%
23.23
+182.95%
-28.01
-22872.36%
0.12
Cash Flow From Continuing Investing Activities
-39.89
-271.68%
23.23
+182.95%
-28.01
-22872.36%
0.12
Net PPE Purchase And Sale
-0.05
+93.24%
-0.77
-2976.00%
-0.03
0.00
Purchase Of PPE
-0.05
+93.24%
-0.77
-2976.00%
-0.03
0.00
Capital Expenditure
-0.05
+93.24%
-0.77
-2976.00%
-0.03
—
Net Investment Purchase And Sale
-39.84
-265.96%
24.00
+185.77%
-27.98
-22852.03%
0.12
Purchase Of Investment
-44.84
-50.73%
-29.75
+12.47%
-33.98
0.00
Sale Of Investment
5.00
-90.70%
53.75
+795.82%
6.00
+4778.05%
0.12
Financing Cash Flow
302.56
+689.67%
38.31
+13.77%
33.68
+46.67%
22.96
Cash Flow From Continuing Financing Activities
302.56
+689.67%
38.31
+13.77%
33.68
+46.67%
22.96
Net Issuance Payments Of Debt
—
0.00
-100.00%
0.72
-97.10%
25.00
Issuance Of Debt
—
0.00
-100.00%
0.72
-97.10%
25.00
Long Term Debt Issuance
—
0.00
-100.00%
0.72
-97.10%
25.00
Net Long Term Debt Issuance
—
0.00
-100.00%
0.72
-97.10%
25.00
Net Common Stock Issuance
327.75
0.00
—
—
Proceeds From Stock Option Exercised
0.25
+973.91%
0.02
+2200.00%
0.00
0.00
Net Other Financing Charges
-25.43
-1389.17%
-1.71
+16.56%
-2.05
+30.52%
-2.95
Changes In Cash
227.47
+2577.03%
8.50
+232.25%
-6.42
-131.56%
20.36
Beginning Cash Position
23.48
+56.73%
14.98
-30.02%
21.40
+1944.32%
1.05
End Cash Position
250.94
+968.93%
23.48
+56.73%
14.98
-30.02%
21.40
Free Cash Flow
-35.26
+34.49%
-53.82
-344.10%
-12.12
-344.24%
-2.73
Interest Paid Supplemental Data
0.00
0.00
-100.00%
1.98
0.00
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Amortization Of Securities
0.26
+867.65%
-0.03
-107.94%
0.43
—
Common Stock Issuance
327.75
0.00
—
—
Issuance Of Capital Stock
327.75
+719.38%
40.00
+14.29%
35.00
+3775.97%
0.90
Net Preferred Stock Issuance
0.00
-100.00%
40.00
+14.29%
35.00
+3775.97%
0.90
Preferred Stock Issuance
0.00
-100.00%
40.00
+14.29%
35.00
+3775.97%
0.90
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category